TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Limbal defect size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal epithelial integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal epithelial stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in body metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in visceral adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in subcutaneous adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Elimination Half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Opioid Use Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in perceived maternal stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With at Least One Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Release of vitreomacular traction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Overall 3D Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Spinal Disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant assessment of procedural pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant assessment of pain or other treatment site responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change from baseline total hairs in the target area (TAHC) of the vertex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to severe ARDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: All-cause Mortality at 28 days
Endpoint domain: Mortality/survival
Primary endpoint: Exhaled breath 8-isoprostane-PGFα
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine 8-isoprostane-PGFα
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Eyes With Any Slit Lamp Findings Greater Than Grade 2
Endpoint domain: Adverse events/effects
Primary endpoint: Abnormalities in connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of MDS-UPDRS part 3 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum Levels of Tumor Necrosis Factor Alpha Receptor 1 (TNFR1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical Global Impression- Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sustained Disease Remission at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Disease Remission at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline %flow-mediated dilation (%FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recommended phase II dose of 17-DMAG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cooking Time Discrepancy Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Range of Stop Times Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Number of Tables Set Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline handgrip strength at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in anal distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Abnormal anal distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Relative glottal gap from laryngeal high-speed videoendoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived voice quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acoustic measure of voice quality (Cepstral Peak Prominence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expanded Skin Fluorescence Intensity Decrease Rate in Venous Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bone mineral density at the hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No 30 Day MACE (Major Adverse Cardiac Events)
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under Curve from 0 to 30 hours (AUCt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Wake time after sleep onset (WASO)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in aortic valve calcium metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in levels of stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in immune function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 40-meter fast-paced walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario McMaster Universities Osteoarthritis Index (WOMAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety as determined by spontaneously reported adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of antibiotic use strategies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cost-effectiveness of antibiotic use strategies
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Beck Anxiety Inventory (BAI) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: tumor targeting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: signal/noise ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Device Leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reportable Variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthcare Costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Exercise participant behavior history
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in airway eosinophil number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline Low density lipoprotein-cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to recurrence of breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the S-warfarin plasma concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the R-warfarin plasma concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skeletal Muscle Function Capacity - Isometric Contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Skeletal Muscle Function Capacity - Isokinetic Contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent Change in Peak Effort Oxygen Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of aerobic bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Diameter of endometrial thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: early implant failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vitamin D serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Individually-corrected QT interval (QTcI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: feasibility and tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With HIV-RNA < 50 Copies/mL at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of ATV/RTV and LPV/RTV at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Trunk-to-Limb Fat Ratio at Week 96
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assisting Hand Assessment performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observer's Assessment of Alertness/Sedation scale (OAA/S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in best-corrected visual acuity (BCVA) ETDRS letter score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of intradialytic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of confirmed treatment failure and relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Prostate cancer related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline knee extension moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline muscle quality assessed via MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline quadriceps muscle activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: glomerular filtration rate (eGFR) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Gap-Kalamazoo Communication Skills Assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quick Disabilities of the arm, shoulder and hand (DASH) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Change in HBsAg (log10 IU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of autologous umbilical cord blood stem cells infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Beam Walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and Tolerability of RPh201
Endpoint domain: Adverse events/effects
Primary endpoint: Change in placement disruptions rates for foster placements
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in visual pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Diaphragmatic excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time Spent With CGM Glucose Levels >180mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-operative meatal stricture
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrent post-operative chordae
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative penile skin scarring
Endpoint domain: Adverse events/effects
Primary endpoint: Failed repair as discovered by the position of the neo-meatus
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative urethral-cutaneous fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Change in delta DSA MFI sum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy of the G-POEM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the time to exhaustion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cardiorespiratory variables - oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in cardiorespiratory variables - heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Western Ontario and McMaster University Osteoarthritis Index (WOMAC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self-Rated Questionnaire SF36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Health Related Quality of Life (HRQoL) 15D
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: on level walking time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stair climbing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With CNS Best Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With CNS Objective Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Level of Fasting Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of hypoxic event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Intensity Ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in 12-lead electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes from baseline in supine blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes from baseline in electrocardiogram (ECG) variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Resting Blood Pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient satisfaction with morning rounds
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Patient satisfaction with provider communication
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Depth of Hypnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain and stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of oral contraceptive components
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral blood velocity in the middle (MCAv) and posterior cerebral arteries (PCAv) during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Parent Treatment Adherence Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parent Satisfaction Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Treatment Fidelity Scale
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in Target Lumen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of irinotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of SN-38
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bowel movement within 4 hours after the first dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence rate of subjects with solicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of subjects with serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: influenza-specific cellular immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: long-term outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration of post-operative ileus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Type of microbiome in peripheral blood sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: B17MP Area Under Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events (dose-escalation stage)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum-tolerated dose (MTD) of liposome-encapsulated daunorubicin-cytarabine (dose-escalation stage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Objective response rate (ORR) (dose-expansion stage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Wagner's wound classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of venous obstructions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Measurement of cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bone metabolism markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: histological type
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Masaoka-Koga stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ITMIG/IASLC 2014/2015 stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of suboptimal PIF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inadequate inhaler choice
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total intra-operative remifentanil consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Edmonton Symptom Assessment Scale (ESAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in NCCN Distress Thermometer
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in severity of PTSD related symptoms as measured by PTSD Checklist (PCL5)
Endpoint domain: Adverse events/effects
Primary endpoint: seroconversion rate of hemagglutination inhibition (HI) antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: geometric mean titer (GMT) of HI antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: perceived exertion for dyspnea
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of pro-inflammatory response over the ICU stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-event pulmonary bacterial superinfection or death
Endpoint domain: Mortality/survival
Primary endpoint: Positive bacteria and/or SARS-CoV-2 cultures on handheld devices
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Prostate Cancer Patients With BRCA2 Mutation Carriers
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Who Complete the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of Scale for the Assessment and Rating of Ataxia (SARA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of Spastic Paraplegia Rating Scale (SPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Graft-vs-host disease response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Endoleak Type I or III
Endpoint domain: Adverse events/effects
Primary endpoint: temperature control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of T cell repertoire analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of recipients with adverse reactions after injection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of recipients with post-vaccination adverse events after injection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of recipients with allergic reactions after injection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of recipients with anaphylaxis after injection
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Pre-dose on the SKAMP Rating Scale Combined Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of atrial fibrillation/flutter episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: degree of overhydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression diagnosis and severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Relapse at 2 Years Post-transplant
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients with osteoporotic fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to First Therapeutic Tacrolimus Trough Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes